Trials / Completed
CompletedNCT02079766
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Accepted
Summary
This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | florbetapir F 18 | 370 megabecquerel (MBq) IV single-dose |
| DRUG | Flortaucipir F18 | 370 megabecquerel (MBq) IV single-dose |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2014-03-06
- Last updated
- 2020-09-07
- Results posted
- 2020-09-07
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02079766. Inclusion in this directory is not an endorsement.